Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta-analysis.

Hongwei CaoTao LiuLi WangQiuhe Ji

Published in: Diabetes, obesity & metabolism (2022)

A clear advantage was demonstrated by SGLT2 inhibitors in reducing the risks of CV and renal events in patients with DKD, compared to GLP-1RAs and DPP-4 inhibitors. We recommend that SGLT2 inhibitors be considered the treatment of choice in patients with DKD.

Keyphrases

type diabetes
climate change
glycemic control
replacement therapy
smoking cessation
wild type
drug induced